Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nedosiran (DCR-PHXC) in Primary Hyperoxaluria Type 3
NCT04555486Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2020
- Primary completion
- Sep 2021
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial in primary hyperoxaluria type 3 (PH3) comparing Nedosiran with Placebo (2 arms). Primary endpoint: Safety profile of a single dose of DCR-PHXC in PH3 Patients. Started Sep 2020; status: completed.
02
Drugs
nedosiran
03
Conditions
primary hyperoxaluria type 3 (PH3)
Beyond the preview
Go deeper on NCT04555486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04555486.